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First described in 1959,1 intravascular large B cell
lymphoma (IVLBCL) is now regarded as a special
variant of extranodal diffuse large B cell lymphoma
(DLBCL). IVLBCL is characterized by the pres-
ence of lymphoma cells in the lumina of small
vessels or capillaries,2 and by an aggressive course
that tends to involve multiple organs such as the
lungs, liver, brain, skin, and bone marrow (BM).
Lymphoma cells can be found in all organs in
autopsied cases.3
The clinical presentations of IVLBCL are exceed-
ingly variable, depending on the organs involved.
Fever and respiratory symptoms are common.
The Asian variant, predominantly Japanese cases,
shows frequent hepatosplenomegaly, BM involve-
ment, thrombocytopenia, and high serum lactate
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Original Article
Intravascular Large B cell Lymphoma in Taiwan: An
Asian Variant of Non-germinal-center Origin
Min-Shu Hsieh,1 Yi-Chen Yeh,2 Yueh-Hung Chou,3 Chung-Wu Lin4*
Background/Purpose: Intravascular large B cell lymphoma (IVLBCL) is a rare variant of diffuse large B cell
lymphoma. We reported the clinical and immunohistochemical characteristics of 10 cases of IVLBCL from
Taiwan between 1995 and 2008.
Methods: Clinical data were reviewed and immunoperoxidase stains were performed with antibodies
against CD20, CD10, Bcl-6, MUM1, and CD5.
Results: There were eight males and two females with a median age of 59 years. Patients presented with
dyspnea (5/10), fever (7/10), splenomegaly (5/10), and bone marrow involvement (8/10). Anemia (9/10),
thrombocytopenia (6/10), and elevated serum lactate dehydrogenase or ferritin levels (8/10) were also
common. Nine cases were CD20+CD10–Bcl-6–, similar to non-germinal center B cells. Six out of seven pa-
tients survived after chemotherapy, but three cases with thrombocytopenia that precluded chemotherapy
died within 2 months.
Conclusion: Our cases of IVLBCL had a non-germinal center B origin and belonged to the Asian variant of this
disease. The liver, spleen, and bone marrow, but rarely the skin or brain, were involved. Thrombocytopenia
is a major risk factor for mortality in these cases.
Key Words: angiotropic lymphoma, fever, intravascular large B cell lymphoma
dehydrogenase (LDH) or ferritin levels, while the
Western variant shows more cutaneous or central
nervous system involvement.4,5 Hemophagocytosis
was observed in 44% of Japanese patients, but
was absent in Western patients.4 The differences in
clinical presentations, however, have no significant
impact on prognosis.
Diagnosis of IVLBCL is difficult because clinical
presentations are nonspecific and nodal involve-
ments are absent. Without prompt chemotherapy,
most patients succumb to the disease in a short
time.
Recently, with cDNA microarrays, DLBCL can
be divided into germinal center B (GCB) and non-
GCB variants. Immunostaining shows that the
GCB variant is CD10+Bcl-6+, and the non-GCB
variant is MUM1+CD10–Bcl-6–. The GCB variant
shows a better overall, or event-free, survival than
the non-GCB variant.6,7 Similar to DLBCL, IVL-
BCL can also be classified into GCB and non-GCB
variants. Most IVLBCLs (87–100%) belong to the
non-GCB variant.4,8 However, there is no signifi-
cant difference in clinical presentations or behav-
iors between GCB and non-GCB variants.3
We reviewed the clinical and pathologic fea-
tures of 10 patients with IVLBCL from Taiwan.
We also used antibodies against CD10, Bcl-6, and
MUM1 to determine the immunophenotypes of
IVLBCL in Taiwanese cases.
Materials and Methods
Patients and clinical data
We searched the files of the Department of Pa-
thology, National Taiwan University Hospital, from
January 1997 to June 2008, and identified seven
cases with the diagnostic features of IVLBCL. Three
additional cases were collected from Taipei Veter-
ans General Hospital and Far Eastern Memorial
Hospital. Clinical data, such as age, sex, clinical
symptoms, laboratory findings, treatments, and
outcomes, were extracted from the medical records.
The study was approved by the institutional review
board of National Taiwan University Hospital and
patients’ confidentiality was protected.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue blocks
were available in nine cases. The specimens 
included two lung biopsies, one adrenal biopsy
and six BM biopsies. The tissue blocks were cut
into sections of 5 μm thickness and stained with
hematoxylin and eosin. Immunohistochemical
studies were performed with monoclonal anti-
bodies against CD5 and CD10 (4C7 and J149,
respectively, from Novocastra, Newcastle upon
Tyne, UK), CD20, Bcl-6, and MUM1 (B-Ly1, PG-
B6p, and MUM1p, respectively, from Dako, Glo-
strup, Denmark). After autoclaving for antigen
retrieval, staining was performed with a Ventana
autostainer (Ventana Medical Systems, Tucson,
AZ, USA) in accordance with the manufacturer’s
instructions.
Results
Clinical features
As shown in Table 1, the eight males and two 
females presented at a median age of 59 years
(range from 42–83 years). Typical of IVLBCL, lym-
phadenopathy was absent in all cases. Nine pa-
tients presented with fever and/or dyspnea. Chest
and abdominal computed tomography disclosed
pleural effusions or increased lung infiltrates in
eight patients, hepatosplenomegaly in two cases,
and splenomegaly in three cases. Laboratory ex-
aminations showed anemia (< 12 g/dL, range
7.6–10.8 g/dL) in nine cases, and thrombocy-
topenia (< 100 × 103/uL, range 15 − 83 × 103/μL)
in six cases. Elevated serum levels of LDH (> 460
U/L) and ferritin (> 377 ng/mL) were found in
five cases and eight cases, respectively.
Histopathology
Diagnosis of IVLBCL was made using liver and
BM biopsies (one case), wedge lung and BM biop-
sies (two cases), BM biopsies (five cases), adrenal
gland biopsy (one case) and skin biopsy (one
case). The liver biopsy from case 1 showed large
atypical lymphoid cells, highlighted by CD20
immunostaining, infiltrating in the sinusoids of
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liver plates (Figure 1A and 1B). The lung biopsies
from case 2 and 5 showed expanded and filled
small vessels and alveolar capillaries containing
lymphoma cells (Figure 1C). The skin biopsy
from case 10 showed capillaries from the superfi-
cial dermis filled by large atypical lymphoma
cells (Figure 1D). The biopsy from case 8 showed
sinusoidal spaces of the adrenal gland expanded
by lymphoma cells, with atrophy of adjacent 
adrenal cortical cells (Figure 1E). The sinusoids
of BM were diffusely involved and often ex-
panded by these large lymphoma cells. In a hy-
pocellular marrow from case 3, BM involvement
was easily identified due to these expanded sinu-
soids (Figure 1F).
Immunohistochemistry
Immunohistochemical stains are summarized in
Table 2. All nine cases were diffusely positive for
CD20 and negative for CD10 or Bcl-6. Five cases
(case 2, 3, 5, 7, and 8) also stained positive for
MUM1. The immunophenotype of IVLBCL sug-
gests a non-GCB origin. Only one case (case 2)
was CD5-positive. Representative illustrations
are shown in Figure 2.
Survival analysis
The treatments and responses to chemotherapy
are listed in Table 3. Six survivors without recur-
rence had a survival time ranging from 20–165
months. Four non-survivors died 0.5, 1, 2, and 14
months following diagnosis. The estimated mean
survival time was 100 months (95% confidence
interval, 43–159 months). Due to the small sam-
ple size, statistical analysis could not be per-
formed on the survivor versus non-survivor groups
(Table 4). However, three of the four lethal cases
(cases 4, 6, and 10) presented with thrombocy-
topenia (< 100 × 103/μL) and deteriorated rapidly
without chemotherapy.
Discussion
According to the World Health Organization clas-
sification of hematopoietic tumors, IVLBCL is
Intravascular large B cell lymphoma
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defined as an extranodal DLBCL with the pres-
ence of malignant lymphoma cells only in the
lumina of small vessels or capillaries, sparing ad-
jacent benign tissue, lymphatic spaces, and lymph
nodes. Because of the unusual intravascular lo-
calization, IVLBCL has been considered as a neo-
plasm of endothelial cells with names such as
“angioendotheliomatosis proliferans systemisata”1
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Figure 1. Histopathology of intravascular large B cell lymphoma. (A) Lymphoma cells (arrow) from case 1 were arranged
along liver sinusoidal spaces. (B) The lymphoma cells were highlighted by CD20 immunostaining. (C) Alveolar capillaries
and small vessels from case 2 were expanded and obliterated by large lymphoma cells (arrow). (D) Capillaries in the 
superficial dermis from case 10 were expanded and filled by large lymphoma cells (arrow). (E) In the adrenal gland from
case 8, sinusoidal spaces were expanded by large lymphoma cells (arrows). (F) Bone marrow biopsies from case 3
showed lymphoma cells filling lumina of capillaries (arrow; hematoxylin and eosin stains; original magnification, 100×).
A
C D
E F
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or “malignant angioendotheliomatosis”. The lym-
phoid nature of IVLBCL was finally established
by immunostaining in the mid 1980s.9,10
In our study, the most common presenting
manifestations were splenomegaly (5/10) and
BM involvement (8/10). Anemia defined as a he-
moglobin level less than < 12 g/dL (9/10), and
thrombocytopenia defined as less than 100 ×
103/μL (6/10). Only one case presented with a
cutaneous rash, and one case had a change in
consciousness that was probably due to hyper-
calcemia but not lymphoma. Also of note was
the absence of lymphadenopathy which is typical
of IVLBCL.
Thus, due to the preferential involvement of
the hematopoietic system but not the skin or
brain, the majority of IVLBCL in Taiwan belong to
the Asian variant, similar in nature to Japan and
other Asian countries. However, unlike Japanese
cases, hemophagocytosis was only found in one
case (case 6) by BM analysis in this study.
Central nervous system involvement in IVLBCL
usually manifests as neurologic deficits, such as
seizures, ataxia, hemiparesis, or dysarthria, remi-
niscent of stroke or encephalitis. None of our pa-
tients had these neurological deficits. Only one
hypercalcemic patient had disturbance in con-
sciousness, which improved after normalization
of serum calcium level. Although head magnetic
resonance imaging for focal ischemic changes and
cerebrospinal fluid studies for the presence of
lymphoma cells were not performed, the absence
of neurological symptoms and signs suggested 
a low probability of central nervous system in-
volvement in our cases.
Dyspnea and fever were common in our study,
as IVLBCL often involves the lungs and fills alve-
olar capillaries with tumor cells. However, fever
in patients with increased pulmonary infiltrates
and sepsis could also be due to infection.
Intravascular large B cell lymphoma
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Table 2. Intravascular large B cell lymphomas
were derived from CD20+CD10–Bcl-6–
non-germinal center B cells*
Case CD20 CD10 Bcl-6 MUM1 CD5
1 + – – – –
2 + – – + +
3 + – – + –
4 + – – – –
5 + – – + –
6 + – – – –
7 + – – + –
8 + – – + –
9 + – – – –
*Immunoperoxidase stains on formalin-fixed paraffin-embedded
tissue sections.
CD20 CD10 BCl-6 MUM1 CD5
Figure 2. Immunohistochemistry of intravascular large B cell lymphoma. Representative immunophenotypes of three 
intravascular large B cell lymphomas are shown. All three cases were CD20+CD10–Bcl-6–, consistent with a non-GCB
phenotype. In addition, the upper case is MUM1–CD5–, the middle case is MUM1+CD5+, and the lower case is
MUM1+CD5– (original magnification, 100×).
Immunohistochemistry of all available speci-
mens revealed that the lymphoma was from a non-
GCB variant in nine cases, as all cases expressed
CD20 (B cell marker), but were negative for the
markers of GCBs (CD10 and Bcl-6). Five cases also
showed nuclear staining for MUM1.
Interestingly, we found one CD5+IVLBCL. CD5
expression is characteristic of chronic lymphocytic
leukemia and mantle cell lymphoma, but can be
rarely detected in a subset of DLBCL, either de novo
or secondary to chronic lymphocytic leukemia
(Richter syndrome). De novo CD5+ DLBCL has
more aggressive clinical features and a poor prog-
nosis.11 CD5 expression was found in 22–75% of
IVLBCL, but the clinical significance of this ob-
servation is still unclear.3,8,12,13
IVLBCL is an aggressive and disseminated dis-
ease. Without prompt chemotherapy, all patients
died in less than 2 months. Patients are often
treated with cyclophosphamide, hydroxydoxoru-
bicin, vincristine, and prednisolone (CHOP); or
CHOP-like regimens with the addition of Rituxi-
mab.8 In a Western series of 38 IVLBCL cases, the
2-year overall survival rate was 30 ± 7%.4 In an
Asian series, the 3-year survival rate ranged from
27% to 32%.3,8 In our series, the estimated mean
survival time was 100 months (95% confidence 
interval, 43–159 months).
There are two case reports of IVLBCL from
Taiwan in the literature. The first was a 49-year-
old woman with progressive limb weakness and
disseminated cerebral neurologic symptoms. Dis-
seminated encephalomyelitis was suspected. She
was treated with steroid pulse therapy and intra-
venous immunoglobulin. The patient died 3
months later. IVLBCL involving the brain, spinal
cord, lungs, kidneys, adrenal glands, breasts, and
uterus was diagnosed by autopsy.14 The second
case was a 39-year-old man with intermittent fever
for 1 year. A Gallium-67 scan revealed diffuse up-
take in the subcutaneous tissues of the abdominal
wall and bilateral thighs. A skin biopsy of the right
M.S. Hsieh, et al
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Table 4. Comparisons between survivors and 
non-survivors*
Characteristics
Survivors Non-survivors 
(n = 6) (n = 4)
Sex (M:F) 5:1 3:1
Age (yr) 62.7 ± 16.3 54.8 ± 7.7
WBC count (/μL) 4751 ± 1545 8112 ± 4123
Hemoglobin (g/dL) 11.2 ± 2.5 8.4 ± 0.7
Platelet (103/μL) 138 ± 74.8 54 ± 29.7
LDH (IU/L) 2025 ± 1713 3411 ± 1992
Chemotherapy (Y:N) 6:0 1:3
*Data presented as n or mean ± standard deviation. M = Male;
F = female; WBC = white blood cell; LDH = lactate dehydrogenase;
Y = yes; N = no.
Table 3. Treatment, responses, and overall survival
Case Chemotherapy Current status Survival (mo)
1 CHOP, BOMES Alive, CR > 148
2 CHOP, BOMES+R Alive, CR > 91
3 COP+R, CNOP+R Alive, CR > 72
4 – Dead 0.5
5 COP, CHOP, ESHAP, BOMES+R Dead 14
6 – Dead 1
7 CHOP+R Alive, CR > 20
8 CEOP Alive, CR > 165
9 CHOP, CHOP+R, COP+R, allogeneic PBSCT Alive, CR > 36
10 – Dead 2
CHOP = Cyclophosphamide, doxorubicin, vincristine, and prednisolone; BOMES = BCNU, vincristine, methotrexate, etoposide, and
methylprednisolone; R = rituximab; COP = cyclophosphamide, vincristine, and prednisolone; CNOP = cyclophosphamide, mitox-
antrone, vincristine, and prednisolone; ESHAP = etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin;
CEOP = cyclophosphamide, etoposide, vincristine, and prednisolone; PBSCT = peripheral blood stem cell transplantation; CR = complete
remission.
Intravascular large B cell lymphoma
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inner thigh revealed IVLBCL. Chemotherapy was
begun and the fever subsided.15
In summary, we reported clinical and patho-
logical findings of 10 Taiwanese cases of IVLBCL,
which was characterized by the absence of lym-
phadenopathy. Our series belonged to the Asian
variant, similar to Japanese reports. All cases
showed a non-GCB immunophenotype. Four
out of 10 cases died, with three cases were char-
acterized by thrombocytopenia that precluded
chemotherapy.
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